Armen Shanafelt
CIK 1656151 · last filed 2022-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$213.64M
Companies
4
Total Filings
22
Lifetime Open-Market Net
$15.29M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Surface Oncology, Inc. (SURF) Delisted | Director | 3,181,817 | $1.07 | $3.40M | $3.99M | 7 | 2022-06-10 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | 135,315 | $12.01 | $1.63M | $549.7K | 8 | 2022-06-09 |
| Rein Therapeutics, Inc. (ALRN) Delisted | Director | 42,249 | $2.11 | $89.1K | $3.75M | 3 | 2018-06-25 |
| PTGX | Director | 1,516,149 | $140.91 | $213.64M | $7.00M | 4 | 2018-06-12 |
Recent Filings · Page 2 of 3
22 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-06 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-25 | Rein Therapeutics, Inc. (ALRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-12 | PTGX | Grant (A) | — | $0 | EDGAR |
| 2018-06-08 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Mixed | +3,447,817 | $3.99M | EDGAR |
| 2017-12-05 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-27 | Rein Therapeutics, Inc. (ALRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-07 | Rein Therapeutics, Inc. (ALRN) Delisted | Mixed | +1,094,987 | $3.75M | EDGAR |
| 2017-05-26 | PTGX | Grant (A) | — | $0 | EDGAR |
| 2016-09-15 | PTGX | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.